SAN FRANCISCO , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an update on the company’s operations. “The completion of enrollment in our Phase 3 ATTRibute-CM
BridgeBio to Acquire All Outstanding Shares of E idos it Does Not Already Own Agreement Brings BridgeBio ’s Clinica l Development and Commercial Development Infrastructure t o Bear Upon E idos’ Acoramidis , Creating Anticipated Value for Patients with ATTR and Investors Agreement
SAN FRANCISCO , Aug. 07, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it has added two new
SAN FRANCISCO , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the second quarter ended June 30, 2020 and provided an update on the company’s operations. “While the COVID-19 pandemic poses an unpredictable threat to our
SAN FRANCISCO , May 08, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations. “We are living in unprecedented times as the impact of the COVID-19
SAN FRANCISCO , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on the company’s recent achievements.
